Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Miao KL, Huang MY, Guo L, Lung K, Armstrong AW. Effect of biologic use on the development of psoriatic arthritis: A population-based study. J Eur[...]

Yan MJ, Chou PP, Roberts AM, Jeong CY, Johnsen N, Katz A, Ma EJ, Nong Y, Armstrong AW. The Colors Beneath: More Than a Skin[...]

Holtsche MM, van Beek N, Hammers CM, Vorobyev A, Kasperkiewicz M, Schumacher N, Muck P, Schmidt E. Adjuvant therapy of severe and/or refractory bullous pemphigoid[...]